Chronomics launches the first consumer epigenetic testing kit and securing investment from VC firm Anthemis
Michael Martin, Partner at Anvil Partners, joined the Board of VTL late last year to help them with their funding and corporate strategies. VTL is a biotech start-up which is developing discoveries by the founder in targeted recruitment of immune cells by viral versions of chemokines, known as virokines, with potential major applications in immunotherapeutics. These could lead to new treatments for infectious and autoimmune diseases, and cancer. VTL is currently setting up a new laboratory at the London Bioscience Innovation Centre and will be initiating pre-clinical studies in the US later this year in a programme supported by the National Institutes of Health (NIH). The associated studies to date have been funded by grants of over £4 million from the Royal Society, BBSRC, Wellcome Foundation, Gates Foundation and the Higher Education Innovation Fund.